<DOC>
	<DOCNO>NCT03074591</DOCNO>
	<brief_summary>This study address , whether treatment IV iron patient heart failure preserve ejection fraction ( HFpEF ) iron deficiency ( ID ) , without anaemia , improve exercise capacity measure 6-minute walking test ( 6-MWT ) symptom safe</brief_summary>
	<brief_title>Effect IV Iron Patients With Heart Failure With Preserved Ejection Fraction</brief_title>
	<detailed_description>All previous trial exclude patient HFpEF . This study address , whether treatment IV iron patient heart failure preserve ejection fraction ( HFpEF ) iron deficiency ( ID ) , without anaemia , improve exercise capacity measure 6-minute walking test ( 6-MWT ) symptom safe . The FAIR-HFpEF study design evaluate efficacy Ferinject® improving symptom HFpEF patient ID . Analyses focus subjective objective measure well patient without anaemia . Furthermore , tolerability safety Ferinject® treatment evaluate .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . Patient willing participate provide write informed consent ; 2 . Age ≥18 year ; 3 . Clinical diagnosis heart failure preserve ejection fraction ( HFpEF ) LVEF ≥45 % screen within 6 month prior plan randomisation ( assessed echocardiography MRI ) ; 4 . Ambulatory least 7 day NYHA class II III time randomisation ( screen visit take place end hospitalisation ) ; 5 . Treated diuretic ; 6 . Presence atrial fibrillation ( AF ) screen randomisation allow 2 4 patient ( calculate per centre ) ; 7 . At screen randomisation , presence one follow criterion : 1. hospitalisation diagnosis HF within 12 month prior plan randomisation ; OR 2. raise plasma level natriuretic peptide patient sinus rhythm ( i.e . patient without AF : NTproBNP &gt; 300 pg/mL BNP &gt; 100 pg/mL MRproANP &gt; 120 pmol/L ; patient AF : NTproBNP &gt; 600 pg/mL BNP &gt; 200 pg/mL MRproANP &gt; 250 pmol/l ) 8 . Evidence diastolic dysfunction screen randomisation , define : 1 . E/E ' &gt; 13 ; OR 2 . LA width ≥38 mm ; OR 3 . LA length ≥50 mm ; OR 4 . LA area ≥20 cm2 ; OR 5 . LA volume ≥55 ml ; OR 6. left atrial volume index &gt; 28 mL/m2 ; 9 . Haemoglobin &gt; 9.0 g/dL ≤14.0 g/dL ( screen ) ; 10 . ID ferritin &lt; 100 ng/mL ferritin 100299 plus TSAT &lt; 20 % ( screen ) ; 11 . 6minutewalking distance baseline &lt; 450 ( average last 2 document test within 8 week prior plan randomisation also need within 20 % ) . 1 . Unable sign inform consent 2 . Any prior echocardiography measurement LVEF &lt; 40 % ; 3 . Clinical sign symptom infection include fever &gt; 38°C ; 4 . Use IV iron , erythropoietin blood transfusion within previous 60 day ; 5 . Use concurrent immunosuppressive therapy ; 6 . History acquire iron overload haemochromatosis ( first relative haemochromatosis ) ; 7 . Known hypersensitivity FCM IV iron product ; 8 . Known bleed haemolytic anemia ; 9 . Presence condition precludes exercise test , decompensated HF , significant musculoskeletal disease , unstable angina pectoris , obstructive cardiomyopathy , severe uncorrected valvular disease , uncontrolled bradyarrhythmias tachyarrhythmias ; 10 . Probable alternative diagnosis opiniton investigator could account patient 's HF symptom severe obesity , primary pulmonary hypertension , chronic obstructive pulmonary disease ( COPD ) ; hence , patient follow exclude : 1 . Severe COPD , i.e . know FEV1 &lt; 50 % , require home oxygen therapy , chronic oral steroid therapy ; 2. body mass index ≥40.0 kg/m2 ; 11 . Presence uncontrolled atrial fibrillation rest heart rate &gt; 110/min ; 12 . Presence uncontrolled hypertension blood pressure &gt; 160/100 mm Hg ; 13 . Renal replacement therapy ; 14 . Concurrent therapy erythropoiesis stimulate agent ; 15 . Known active malignancy ; 16 . Known HIV active hepatitis infection ; 17 . Pregnancy ; 18 . Patients , may dependent sponsor , investigator trial site , exclude trial 19 . Lack willingness storage disclosure pseudonymous disease data context clinical trial . 20 . Participation another clinical trial within previous 30 day and/ anticipated participation another trial study . 21 . Inability fully comprehend and/or perform study procedure investigator 's opinion ; 22 . Persons stay institution due order national body court law .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Iron deficiency</keyword>
	<keyword>Heart failure</keyword>
</DOC>